Renal Retention of Microbubbles
This study is not yet open for participant recruitment.
Verified July 2012 by Oregon Health and Science University
Sponsor:
Oregon Health and Science University
Information provided by (Responsible Party):
Jonathan R. Lindner, MD, Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT01647464
First received: July 19, 2012
Last updated: July 20, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Flank pain has been reported with ultrasound (US) contrast agents. The purpose of this study is to determine whether there is retention of ultrasound contrast agents in the renal microcirculation, which has been described in mice.
| Condition |
|---|
|
- Study Focus: Renal Retention of Lipid Microbubbles |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Study of Whether There is Renal Retention of Lipid Microbubble Ultrasound Contrast Agents |
Further study details as provided by Oregon Health and Science University:
Primary Outcome Measures:
- Renal retention of microbubbles [ Time Frame: 10 min ] [ Designated as safety issue: No ]Video intensity in the renal circulation 10 min after completion of a clinically indicated contrast echocardiography study.
| Estimated Enrollment: | 12 |
| Study Start Date: | July 2012 |
| Estimated Study Completion Date: | October 2012 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Contrast administration
Patients undergoing contrast-enhanced echo.
|
Detailed Description:
In this study patients undergoing clinically indicated contrast echocardiography will have renal ultrasound performed 10 minutes after completion of contrast infusion to determine the presence and location of renal retention of lipid microbubbles.
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients undergoing contrast echocardoigraphy
Criteria
Inclusion Criteria:
- Undergoing clinically indicated contrast echo
- adequate renal ultrasound images
Exclusion Criteria:
- chronic inflammatory disease
- known kidney disease
- immunomodulatory therapy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01647464
Contacts
| Contact: Jonathan R Lindner, MD | 5034948750 | lindnerj@ohsu.edu |
| Contact: Todd Belcik, RDCS | 5034948750 | belcikt@ohsu.edu |
Locations
| United States, Oregon | |
| Oregon Health & Science University | Recruiting |
| Portland, Oregon, United States, 97239 | |
| Contact: Jonathan Lindner, MD | |
| Principal Investigator: Jonathan R Lindner, MD | |
Sponsors and Collaborators
Oregon Health and Science University
More Information
No publications provided
| Responsible Party: | Jonathan R. Lindner, MD, Professor of Medicine, Oregon Health and Science University |
| ClinicalTrials.gov Identifier: | NCT01647464 History of Changes |
| Other Study ID Numbers: | MBretention |
| Study First Received: | July 19, 2012 |
| Last Updated: | July 20, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Urinary Retention Urination Disorders Urologic Diseases |
ClinicalTrials.gov processed this record on May 22, 2013